Theresa L. Werner
Professor
Department of Oncological Sciences
Huntsman Cancer Institute
United States of America
Biography
Theresa L. Werner, M.D., is an assistant professor in the Division of Oncology, Department of Medicine, at the University Of Utah School Of Medicine, an Investigator at the Huntsman Cancer Institute, and a member of the Experimental Therapeutics Program. Dr. Werner is a specialist in adult hematology and medical oncology, and her main areas of interest include breast cancer and gynecologic malignancies (cancers of the ovary, uterus, cervix, and vagina). Dr. Werner earned her bachelor’s degree from Indiana University in Bloomington, Indiana, and her medical degree from Indiana University School of Medicine, in Indianapolis, Indiana. She then completed a residency in internal medicine and a chief medical residency at the University Of Utah School Of Medicine, where she received awards for excellence in teaching and the clinical care of patients. Dr. Werner then completed a fellowship in hematology and medical oncology at the University of Utah and the Huntsman Cancer Institute. She is board certified in internal medicine, hematology, and oncology. Dr. Werner is a member of the gynecologic and breast cancer programs at the Huntsman Cancer Institute. She sees patients with these types of cancers in her clinic as well as those patients at high risk for breast and ovarian cancer in the Family Cancer Assessment Clinic. Dr. Werner is a member of several professional societies including the American Society of Clinical Oncology, the Southwest Oncology Group, and the Gynecology Oncology Group, where she serves as a member of the Medical Oncology Committee. She also serves on the National Cancer Institute’s Cervical Cancer Task Force and the National Cancer Comprehensive Network (NCCN) Panel for Ovarian Cancer which defines national standards for the oncologic care of ovarian cancer. Dr. Werner is heavily involved in clinical and translational research and is active in the experimental therapeutics and phase one clinical trial program. Dr. Werner serves as the principal investigator for numerous clinical trials in breast and gynecologic cancers.
Research Interest
Breast Cancer Cervix Neoplasms Ovarian Neoplasms Uterine Neoplasms Breast Neoplasms Clinical Trials, Phase I
Publications
-
Camp NJ, Lin WY, Bigelow A, Burghel GJ, Mosbruger TL, Parry MA, Waller RG, Rigas SH, Tai PY, Berrett K, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Factor RE, Bernard PS, Cannon-Albright L, Knight S, Abo R, Werner TL, Reed MW, Gertz J, Cox A (2016). Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Res, 76(7), 1916-25.
-
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
-
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
